Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 72,320 |
|
|||||
| News | - | ||||||
| Day High | 16.6263 | Low High |
|||||
| Day Low | 15.84 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| PepGen Inc | PEPG | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.02 | -0.12% | 16.33 | 16:02:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 16.60 | 15.84 | 16.6263 | 16.33 | 16.35 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,121 | 72,320 | $ 16.09 | $ 1,163,857 | - | 3.72 - 17.51 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:02:58 | 23 | $ 16.33 | USD |
PepGen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 528.35M | 32.35M | - | 0 | -78.63M | -2.43 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
PepGen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PEPG Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 14.38 | 17.23 | 13.77 | 15.49 | 87,107 | 1.95 | 13.56% |
| 1 Month | 14.50 | 17.23 | 12.30 | 14.31 | 67,211 | 1.83 | 12.62% |
| 3 Months | 14.29 | 17.23 | 10.215 | 13.80 | 73,719 | 2.04 | 14.28% |
| 6 Months | 4.65 | 17.51 | 4.30 | 12.31 | 98,455 | 11.68 | 251.18% |
| 1 Year | 14.33 | 17.51 | 3.72 | 10.26 | 80,376 | 2.00 | 13.96% |
| 3 Years | 15.60 | 20.00 | 3.72 | 11.24 | 102,235 | 0.73 | 4.68% |
| 5 Years | 15.60 | 20.00 | 3.72 | 11.24 | 102,235 | 0.73 | 4.68% |
PepGen Description
| PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. |
